Structure of the neutron mid-shell nuclei $^{111,113}_{\quad \ 47}$Ag$_{64,66}$

Autor: Lalkovski, S., Stefanova, E. A., Kisyov, S., Korichi, A., Bazzacco, D., Bergström, M., Görgen, A., Herskind, B., Hübel, H., Jansen, A., Khoo, T. L., Kutsarova, T., Lopez-Martens, A., Minkova, A., Podolyák, Zs., Schönwasser, G., Yordanov, O.

Publikováno v: Phys. Rev. C 96, 044328 (2017)

$^{111}$Ag and $^{113}$Ag were produced in induced fission reaction, where yrast and near-yrast states were populated. To interpret the new data the Interacting Boson-Fermion model was used. A good agreement with the experimental data is achieved, su

Externí odkaz: http://arxiv.org/abs/1709.06739

Self-esteem in children in joint physical custody and other living arrangements

Autor: Turunen, J., Fransson, E., Bergström, M.

Publikováno v: In Public Health August 2017 149:106-112

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Autor: Wechalekar, A, Antoni, G, Al Azzam, W, Bergström, M, Biswas, S, Chen, C, Cheriyan, J, Cleveland, M, Cookson, L, Galette, P, Janiczek, RL, Kwong, RY, Lukas, MA, Millns, H, Richards, D, Schneider, I, Solomon, SD, Sörensen, J, Storey, J, Thompson, D, van Dongen, G, Vugts, DJ, Wall, A, Wikström, G, Falk, RH

Publikováno v: Wechalekar, A, Antoni, G, Al Azzam, W, Bergström, M, Biswas, S, Chen, C, Cheriyan, J, Cleveland, M, Cookson, L, Galette, P, Janiczek, R L, Kwong, R Y, Lukas, M A, Millns, H, Richards, D, Schneider, I, Solomon, S D, Sörensen, J, Storey, J, Thompson, D, van Dongen, G, Vugts, D J, Wall, A, Wikström, G & Falk, R H 2022, ' Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis : an open-label Phase 2 study and an adjunctive immuno-PET imaging study ', BMC Cardiovascular Disorders, vol. 22, no. 1, 49 . https://doi.org/10.1186/s12872-021-02407-6
BMC Cardiovascular Disorders, 22(1). BioMed Central
BMC Cardiovascular Disorders, 22(1):49. BioMed Central

Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d43a27d4681e51d8685ea3c4e47388
https://doi.org/10.1186/s12872-021-02407-6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.